The Myth of Belgium's ‘Cautious Approach’

Key Takeaways

• Flanders hosts seven gender clinics for 6.7 million people
• CSG’s pediatric service lacks transparent assessment protocols
• Clinic’s self‑referral policy permits minors without parental consent
• Five post‑hysterectomy suicides raise safety concerns

Pulse Analysis

Flanders’ gender‑care ecosystem has expanded rapidly, now comprising seven clinics for a population smaller than Greater London. The centerpiece, Ghent University Hospital’s Centrum voor Seksualiteit en Gender (CSG), markets a multidisciplinary, "careful" approach, yet public documents reveal scant detail on diagnostic criteria or screening processes. This opacity contrasts sharply with the UK’s Cass Review, which called for heightened caution and highlighted the weak evidence base for pediatric transition. By endorsing only the review’s resource‑allocation recommendations while rejecting calls for a moratorium on puberty blockers, Flemish clinicians appear to sidestep the most contentious findings.

The lack of transparent protocols has tangible consequences. CSG accepts self‑referrals from minors, often without parental consent or external medical evaluation, a practice that raises ethical red flags given the irreversible nature of many interventions. Moreover, the clinic’s published data disclose five suicides among patients who underwent hysterectomies, translating to a 3.4 percent mortality rate within that subgroup—far above national averages. These outcomes suggest that current safeguards may be insufficient to identify youth at risk of detransition or adverse mental‑health events, reinforcing calls for rigorous, evidence‑based assessment frameworks.

Beyond the immediate clinical concerns, the post underscores systemic incentives that may drive over‑diagnosis. Practitioners’ careers and clinic revenue depend on a steady flow of patients diagnosed with gender incongruence, a psychiatric label lacking clear biological markers. This dynamic mirrors broader debates in gender‑affirming medicine worldwide, where the balance between affirming care and protecting vulnerable patients remains unsettled. Policymakers, insurers, and professional bodies in Europe should consider stricter oversight, mandatory multidisciplinary reviews, and transparent reporting to ensure that the promise of "careful" treatment translates into measurable safety and accountability.